Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Pepper-Based patch may ease Post-Surgery nerve pain better than pills

NCT ID NCT03794388

Symptom relief Sponsor: Institut Cancerologie de l'Ouest Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a capsaicin skin patch (made from chili peppers) works better than oral pregabalin for treating nerve pain that starts soon after breast cancer surgery. 140 women who had surgery for breast cancer and developed nerve pain within 2 months were enrolled. The goal was to see if early treatment with the patch could prevent long-term chronic pain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

140 people

The number who actually took part.

Started

Mar 2019

Finished

Nov 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female who had first breast cancer surgery, regardless of the type of surgery * Age ≥ 18 years * Healthy, non-irritated skin on painful areas to treat * During the inclusion visit to M4 post surgery, neuropathic pain of the breast and / or axillary area corresponding to inter-brachial neuralgia with a DN4≥4 score. * Obtaining the signed written consent of the patient * Major patient affiliated to a social security scheme Exclusion Criteria: * Contraindications specific to the treatments studied : capsaicine and pregabalin * Diabetic patient * Previous treatment with capsaicin or pregabalin * Opioid treatment\> 80 mg / day (oral morphine equivalent) in progress- Topical treatment of pain between surgery and inclusion visit * Uncontrolled hypertension (systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 90 mmHg) or recent history (\<3 months) of cardiovascular events (stroke, heart attack, pulmonary embolism) * Creatinine clearance (CLcr) \<60mL / min according to the Cockcroft-Gault formula * Pregnant woman, likely to be pregnant or breastfeeding * Persons deprived of their liberty or guardianship (including curators), * Impossibility of submitting to the medical follow-up of the test for geographical, social or psychological reasons

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer patient are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer patient

Contacts and locations

Locations

  • CHU NICE

    Nice, 06003, France

  • Centre Leon Berard

    Lyon, 69008, France

  • Centre Oscar Lambret

    Lille, 59020, France

  • Ch Valenciennes

    Valenciennes, 53322, France

  • Chd Vendee

    La Roche-sur-Yon, 85025, France

  • Chu Grenoble

    Grenoble, 38700, France

  • Hopital Saint Vincent de Paul

    Lille, 59020, France

  • Institut Curie

    Saint-Cloud, 92210, France

  • Institut Jean Godinot

    Reims, 51100, France

  • Institut de Cancerologie de L'Ouest

    Angers, 49000, France

  • Iuct Oncopole

    Toulouse, 31052, France